Anti-dCD20c1-dIgG2

Monoclonal dog IgG2 antibody against dog CD20

Anti-dCD20c1-dIgG2 is a chimeric monoclonal antibody specific for dog CD20 (dCD20). TIn flow cytometry applications, this antibody has exhibited weak cross-reactivity with human CD20. Reactivity with other species has not been tested.

It has been produced in CHO cells and purified by affinity chromatography with protein A.

Anti-dCD20c1-dIgG2 was generated by combining the constant domains of the dog IgG2 molecule with the variable regions of Anti-dCD20c1-mIgG2a.

Anti-dCD20c1-mIgG2a has been selected for its ability to bind dCD20 and induce complement-dependent cytotoxicity (CDC).

Specifications

Clonality: Monoclonal antibody

Specificity: Targets cells expressing dog CD20

Isotype: Dog IgG2, kappa

Clone: 6C12

Formulation: 0.2 µm filtered solution in 68 mM phosphate buffer with 91 mM glycine, 5% w/v saccharose and stabilizing agents

Quality control:

• The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is confirmed by using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
• Recognition of dCD20 with this antibody is tested using flow cytometry.

Applications: Flow cytometry, cell lysis, B-cell depletion

Not suitable for immunohistochemical staining.

Contents

100 µg purified anti-dCD20c1-dIgG2 antibody, provided azide- free and lyophilized.

Product is shipped at room temperature.

Store lyophilized antibody at -20°C.

Description

CD20 is a transmembrane phosphoprotein that is expressed on the surface of malignant and normal B lymphocytes.

As CD20 expression is restricted to B cells, this antigen is a useful marker or target for B-cell lymphomas [1].
Studies demonstrate that the expression of CD20 correlates with B-cell lymphoma in dogs [2]. In human medicine, an anti-human CD20 monoclonal antibody (Rituximab) has been approved by the FDA to treat B-cell non-Hodgkin's lymphoma resistant to other chemotherapy regimens.

Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab was tested for B-cell binding and depletion in canine B-cells ex vivo; however, this human therapeutic is not able to bind or deplete canine B-cells [3, 4]. Thus, there is a need for specific antibodies directed against dog CD20.

Such antibodies can be used to investigate CD20 as a therapeutic target in canine lymphoma.

1. Kosmas C. et al., 2002. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 16(10):2004-15.
2. Jubala C. et al., 2005. CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma. Vet. Path. 42:468-76.
3. Crow S., 2008. Chemoimmunotherapy for canine lymphoma: tumor vaccines and monoclonal antibodies. Cancer Therapy 6;181-6.
4. Impellizeri J. et al., 2006. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. Vet. J. 171:556-8.
5. Rütgen B. et al., 2010. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res. 4(7):932-8.